ketamine + midazolam + ketamine + propofol

The name 'ketamine + midazolam + ketamine + propofol' refers to the pharmacological components of two distinct sedation regimens compared in a randomized, single-blind clinical trial (NCT06368219) conducted by Alexandria University. The study evaluates the efficacy and safety of combining ketamine (a dissociative anesthetic and NMDA receptor antagonist) with either midazolam (a benzodiazepine and GABA-A receptor positive allosteric modulator) or propofol (a sedative-hypnotic and GABA-A receptor modulator) for procedural sedation in adult emergency department patients. These combinations, often colloquially referred to as 'keta-mid' and 'ketofol', are used to provide analgesia and sedation while potentially minimizing the adverse effects associated with higher doses of the individual agents. The trial specifically compares the incidence of complications between these two regimens in an emergency setting.

Other names

Ketamine-Midazolam vs Ketamine-PropofolKetamine + MidazolamKetamine + Propofol